Dose-dependent effects of n-3 polyunsaturated fatty acids on platelet activation in mildly hypertriglyceridemic subjects

Journal of Medicinal Food

Volumn 12, Issue 4, 2009, Pages 809-813

  Park, Yongsoon ^a   Harris, William S ^b,c  

^a Hanyang University   (South Korea)

^b SANFORD RESEARCH   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Hypertriglyceridemia; N 3 polyunsaturated fatty acids; Platelet

Indexed keywords

COLLAGEN; CORN OIL; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; EX VIVO STUDY; FEMALE; HEART PROTECTION; HEAT; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; COLD TEMPERATURE; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, OMEGA-3; FEMALE; HOT TEMPERATURE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET COUNT;

MOROCCAN PEPPER VIRUS; ZEA MAYS;

EID: 70149086280     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2008.1097     Document Type: Article

References (34)

1. Willans DJ, Mill SC, Ranney EK: Common thrombotic disorders defined by CBC platelet parameters. Clin Appl Thromb Hemost 1995;1:188-201.
2. Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G: Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002;117: 399-404.
3. Bath P, Algert C, Chapman N, Neal B: Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004;35:622-626.
4. Sharpe PC, Trinick T: Mean platelet volume in diabetes mellitus. Q J Med 1993;86:739-742.
5. Schoene NW: Design criteria: tests used to assess platelet function. Am J Clin Nutr 1997;65(5 Suppl):1665S-1668S.
6. Winokur R, Hartwig JH: Mechanism of shape change in chilled human platelets. Blood 1995;85:1796-1804.
7. Borst C, Bos AN, Zwaginga JJ, Rienks R, de Groot PG, Sixma JJ: Loss of blood platelet adhesion after heating native and cultured human subendothelium to 100 degrees Celsius. Cardiovasc Res 1990;24:665-668.
8. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E in 11,324 patients with myocardial infarction: results of the GISSI-Prevenzione Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354: 447-455.
9. Burr ML, Holliday MA, Fehily AM, Whitehead P: Haematological prognostic indices after myocardial infarction. Evidence from the Diet and Reinfarction Trial (DART). Eur Heart J 1992;13:166-170.
10. Brox J, Olaussen K, Østerud B, Elvevoll EO, Bjørnstad E, Brenn T, Brattebø G, Iversen H: A long-term seal- and cod-liver-oil supplementation in hypercholesterolemic subjects. Lipids 2001; 36:7-13.
11. Goodnight SH Jr, Harris WS, Connor WE: The effects of dietary omega-3 fatty acids on platelet composition and function in man: a prospective, controlled study. Blood 1981;58:880-885.
12. Nelson GJ, Schmidt PC, Corash L: The effect of a salmon diet on blood clotting, platelet aggregation and fatty acids in normal adult men. Lipids 1991;26:87-96.
13. Wander RC, Patton BD: Comparison of three species of fish consumed as part of a Western diet: effects on platelet fatty acids and function, hemostasis, and production of thromboxane. Am J Clin Nutr 1991;54:326-333.
14. Shikano M, Masuzawa Y, Yazawa K, Takayama K, Kudo I, Inoue K: Complete discrimination of docosahexaenoate from arachidonate by 85 kDa cytosolic phospholipase A2 during the hydrolysis of diacyl- and alkenylacylglycerophosphoethanol-amine. Biochim Biophys Acta 1994;1212:211-216.
15. Park Y, Harris W: EPA, but not DHA, decreases mean platelet volume in normal subjects. Lipids 2002;37:941-946.
16. Bayon Y, Croset M, Daveloose D, Guerbette F, Chirouze V, Viret J, Kader JC, Lagarde M: Effect of specific phospholipid molecular species incorporated in human platelet membranes on thromboxane A2=prostaglandin H2 receptors. J Lipid Res 1995 36:47-56.
17. von Schacky C, Weber PC: Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985;76:2446-2450.
18. Park Y, Schoene N, Harris W: Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002;13:301-306.
19. Isley WL, Park Y, Harris W: The effect of high dose simvastatin on, platelet size in patients with, type 2 diabetes mellitus. Platelets 2006;17:292-295.
20. McGill DA, Ardlie NG: Abnormal platelet reactivity in men with premature coronary heart diseases. Res Clin Pract 1988;5:889-900.
21. Negrescu EV, de Quintana KL, Siess W: Platelet shape change induced by thrombin receptor activation. Rapid stimulation of tyrosine phosphorylation of novel protein substrates through an integrin- and Ca2p-independent mechanism. J Biol Chem 1995; 270:1057-1061.
22. Hirai A, Terano T, Makuta H, Kobayashi S, Makuta H, Ozawa A, Fujita T, Tamura Y, Kitagawa H, Kumagai A, Yoshida S: Effect of oral administration of highly purified eicosapentaenoic acid and docosahexaenoic acid on platelet function and serum lipids in hyperlipidemic patients. Adv Prostaglandins Thromboxane Leukot Res 1989;19:627-630.
23. Terano T, Hirai A, Hamazaki T, Kobayashi S, Fujita T, Tamura Y, Kumagai A: Effect of oral administration of highly purified eicosapentaenoic acid on platelet function, blood viscosity and red cell deformability in healthy human subjects. Atherosclerosis 1983;46:321-331.
24. Nelson GJ, Schmidt PS, Bartolini GL, Kelley DS, Kyle D: The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 1997;32:1129-1136. (Pubitemid 27508104)
25. Driss F, Vericel E, Lagarde M, Dechavanne M, Darcet P: Inhibition of platelet aggregation and thromboxane synthesis after intake of small amounts of eicosapentaenoic acid. Thromb Res 1984;36:389-396.
26. Croset M, Guichardant M, Lagarde M: Different metabolic behavior of long-chain n-3 polyunsaturated fatty acids in human platelets. Biochim Biophys Acta 1988;961:262-269.
27. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR: Ei-cosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet 1978;23:117-119.
28. Parent CA, Lagarde M, Venton DL, Le Breton GC: Selective modulation of the human platelet thromboxane A2=prostaglandin H2 receptor by eicosapentaenoic and docosahexaenoic acids in intact platelets and solublized platelet membranes. J Biol Chem 1992;267:6541-6547.
29. van Rollins M: Epoxygenase metabolites of docosahexaenoic and eicosapentaenoic acids inhibit platelet aggregation at concentrations below those affecting thromboxane synthesis. J Pharmacol Exp Ther 1995;274:798-804.
30. Yeo YK, Philbrick DJ, Holub BJ: The effect of long-term consumption of fish oil on platelet-activating factor synthesis in rat renal microsomes. Biochem Biophys Res Commun 1989;160: 1238-1242.
31. Fuchs J, Beigel Y, Green P, Zloikamien B, Davidson E, Roten-berg Z, Weinberger I: Big platelets in hyperlipidemic patients. J Clin Pharmacol 1992;32:639-642.
32. Englyst NA, Taube JM, Aitman TJ, Baglin TP, Byrne CD: A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes 2003;52:1248-1255.
33. Chetty N, Naran NH: Platelet hyperreactivity in hyperlipidaemia with specific reference to platelet lipids and fatty acid composition. Clin Chim Acta 1992;213:1-13.
34. Fuhrman B, Brook JG, Aviram M: Increased platelet aggregation during alimentary hyperlipemia in normal and hypertriglyceri-demic subjects. Ann Nutr Metab 1986;30:250-260.